Policy & Regulation
Labcorp, Charles River and FDA collaborate on advancing preclinical methods for evaluating drug abuse potential
23 October 2026 - Laboratory services provider Labcorp (NYSE:LH) announced on Thursday a collaboration with the US Food and Drug Administration (FDA) and pharmaceutical research services provider Char...
HUYABIO International reports positive Phase 3 trial results for HBI-8000 and nivolumab combination
23 October 2026 - Biopharmaceutical company HUYABIO International announced on Thursday that oral HBI-8000 in combination with intravenous nivolumab reduced the risk of disease progression or death by...
Harbour BioMed's batoclimab injection receives Chinese regulatory approval to treat generalised myasthenia gravis
23 October 2026 - Chinese biopharmaceutical company Harbour BioMed (HKEX:02142) announced on Thursday that China's National Medical Products Administration (NMPA) has approved the Biologics Licen...
NFL Biosciences secures regulatory approval to launch Phase 2 trial of NFL-102
22 October 2026 - French biopharmaceutical company NFL Biosciences (Euronext Growth Paris:ALNFL) announced on Thursday that has received approval from France's National Agency for Medicines and H...
ProBio's Nanjing biologics manufacturing facility completes Chinese regulatory pre-approval inspection
22 October 2026 - ProBio Inc, a China-based global contract research, development and manufacturing organisation (CRDMO), announced on Wednesday the successful completion of a Pre-Approval Inspection ...
Lynch Regenerative Medicine's Phase IIb clinical trial of rhPDGF-BB injection cleared by FDA
22 October 2026 - Regenerative aesthetics company Lynch Regenerative Medicine LLC (LRM) announced on Wednesday that its Investigational New Drug (IND) application for a Phase 2 clinical trial evaluati...